文献速递糖尿病

数据驱动2型糖尿病亚组与简单临床特征模型在疾病进展和治疗反应中的比较

Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data.
PubMed 文献 · Lancet Diabetes Endocrinol · 2019-04-29

该研究在ADOPT试验(n=4351)中识别五个数据驱动聚类,并在RECORD试验(n=4447)中比较聚类与简单临床特征选择降糖治疗的效用。聚类在血糖和肾脏进展及治疗反应上存在差异,但基于简单连续临床特征的模型分层患者更有用。提示2型糖尿病精准医学应针对特定结局使用特定表型指标,而非将患者分配到亚组。

要点

  • 数据驱动聚类在血糖进展上差异,但仅用诊断年龄解释的变异相似。
  • 基线eGFR比聚类更好地预测慢性肾病时间。
  • 简单临床特征选择治疗优于聚类,精准医学应针对特定结局。

核心结论

  • 数据驱动聚类在糖尿病进展和治疗反应上有差异,但基于简单连续临床特征的模型对患者分层更有用。

研究设计与样本

  • 在ADOPT试验(n=4351)中采用Ahlqvist等的数据驱动聚类分析识别五个聚类,并在RECORD试验(n=4447)中比较聚类与简单临床特征选择降糖治疗的效用。

主要发现

  • 聚类在血糖进展上有差异,但仅用诊断年龄解释的变异相似。
  • 聚类间慢性肾病发病率有差异,但基线eGFR是慢性肾病时间的更好预测指标。
  • 聚类在血糖反应上有差异,噻唑烷二酮类对严重胰岛素抵抗型糖尿病聚类患者有特别益处,磺脲类对轻度年龄相关型糖尿病聚类患者有特别益处。
  • 简单临床特征在个体患者选择治疗上优于聚类。

关键数值与推荐

  • 使用诊断年龄预测血糖进展,基线肾功能预测肾脏进展;选择治疗时结合性别、BMI、诊断年龄、基线HbA1c。

临床怎么用

  • 临床应考虑使用特定表型指标预测特定结局,而非将患者分配到数据驱动亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Research using data-driven cluster analysis has proposed five subgroups of diabetes with differences in diabetes progression and risk of complications. We aimed to compare the clinical utility of this subgroup-based approach for predicting patient outcomes with an alternative strategy of developing models for each outcome using simple patient characteristics. METHODS: We identified five clusters in the ADOPT trial (n=4351) using the same data-driven cluster analysis as reported by Ahlqvist and colleagues. Differences between clusters in glycaemic and renal progression were investigated and contrasted with stratification using simple continuous clinical features (age at diagnosis for glycaemic progression and baseline renal function for renal progression). We compared the effectiveness of a strategy of selecting glucose-lowering therapy using clusters with one combining simple clinical features (sex, BMI, age at diagnosis, baseline HbA1c) in an independent trial cohort (RECORD [n=4447]). FINDINGS: Clusters identified in trial data were similar to those described in the original study by Ahlqvist and colleagues. Clusters showed differences in glycaemic progression, but a model using age at diagnosis alone explained a similar amount of variation in progression. We found differences in incidence of chronic kidney disease between clusters; however, estimated glomerular filtration rate at baseline was a better predictor of time to chronic kidney disease. Clusters differed in glycaemic response, with a particular benefit for thiazolidinediones in patients in the severe insulin-resistant diabetes cluster and for sulfonylureas in patients in the mild age-related diabetes cluster. However, simple clinical features outperformed clusters to select therapy for individual patients. INTERPRETATION: The proposed data-driven clusters differ in diabetes progression and treatment response, but models that are based on simple continuous clinical features are more useful to stratify patients. This finding suggests that precision medicine in type 2 diabetes is likely to have most clinical utility if it is based on an approach of using specific phenotypic measures to predict specific outcomes, rather than assigning patients to subgroups. FUNDING: UK Medical Research Council.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Dennis JM, Shields BM, Henley WE, et al. Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol. 2019. PMID: 31047901. doi:10.1016/S2213-8587(19)30087-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。